The fight against drug-resistant bacteria marches forward as Adaptive Phage earns $40M+ Series B
A company working toward the field of bacteriophages, developing therapies that use bacteria-killing viruses, just pulled in a significant amount of new capital.
Adaptive Phage …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
